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Several drugs and their associations are being used for adjuvant or complementary chemotherapy with the aim of improving
results of gastric cancer treatment. The objective of this study was to verify the impact of these drugs on nutrition and on survival
rate after radical treatment of 53 patients with gastric cancer in stage III of the TNM classification. A control group including 28
patients who had only undergone radical resection was compared to a group of 25 patients who underwent the same operative
technique followed by adjuvant polychemotherapy with FAM (5-fluorouracil, Adriamycin, and mitomycin C). In this latter group,
chemotherapy toxicity in relation to hepatic, renal, cardiologic, neurological, hematologic, gastrointestinal, and dermatological
functions was also studied.
There was no significant difference on admission between both groups in relation to gender, race, macroscopic tumoral type of
tumor according to the Borrmann classification, location of the tumor in the stomach, length of the gastric resection, or response to
cutaneous tests on delayed sensitivity. Chemotherapy was started on average, 2.3 months following surgical treatment. Clinical and
laboratory follow-up of all patients continued for 5 years. The following conclusions were reached: 1) The nutritional status and
incidence of gastrointestinal manifestation were similar in both groups; 2) There was no occurrence of cardiac, renal, neurological,
or hepatic toxicity or death due to the chemotherapeutic method per se; 3) Dermatological alterations and hematological toxicity
occurred exclusively in patients who underwent polychemotherapy; 4) There was no significant difference between the rate and site
of tumoral recurrence, the disease-free interval, or the survival rate of both study groups; 5) Therefore, we concluded, after a 5-year
follow-up, chemotherapy with the FAM regimen did not increase the survival rate.
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The survival rate of patients under-
going surgical treatment of gastric can-
cer in the Western World is disappoint-
ing, especially when compared to Japa-
nese centers1. Such a difference may be
explained by the low number of pa-
tients with early diagnosis in the West-
ern World, while in Japan most patients
are operated on while still early cancer
carriers2. Since the results of surgery in
patients with advanced gastric cancer
are disappointing, it is natural that
other therapeutic modalities that may
either complement or replace surgery
are being researched. Systemic neo-
plastic chemotherapy is the best hope
for neutralizing microscopic neoplastic
foci, which are impossible to extirpate
during surgery3,4,5.
It has not yet been established in
the literature that chemotherapy, either
with single or multiple drugs, increases
the survival rate, although the more re-
sponsive patients to this treatment are
those who live longer6. The objective
of using the chemotherapeutic scheme
is to increase survival, provided that it
does not produce significant side-ef-
fects that may impair the quality of life
of patients who undergo surgery for
gastric cancer7.
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The objectives of this study are: 1)
to investigate the effect of the FAM (5-
fluorouracil, Adriamycin, and mitomy-
cin C) regimen—as well as its toxic-
ity—on the postoperative nutritional sta-
tus of patients; 2) to analyze the impact
of polychemotherapy with FAM on the
5-year survival rate of patients undergo-
ing radical surgical treatment for stage
III gastric cancer (TNM classification).
PATIENTS AND METHODS
The study included 53 patients with
advanced stage III gastric adenocarci-
noma (TNM classification of UICC)8.
All patients underwent level D2 radi-
cal resection. This terminology was
adopted following a suggestion of the
German authors and acceptance by the
Japanese (Japanese Classification of
Gastric Carcinoma – Japanese Re-
search Society for Gastric Cancer,
1995)9 instead of the previous termi-
nology – R2 – currently reserved to
identify radicality.
After the operation the patients en-
tered a controlled prospective and non-
randomized study, with two groups as
follows: Group I (FAM), including 25
patients who, besides having under-
gone surgical treatment, received adju-
vant polychemotherapy under the FAM
regime; Group II, control (C), made up
of 28 patients who only underwent sur-
gical treatment.
The average age of patients in
Group I (FAM) was 51.80 (±10.39)
and in Group II (C) 56.93 (±7.30)
years (Student’s test  t= 2.09; p=
0.0205). Patients of both groups had
the same stage (III) gastric cancers, and
the distribution according to gender,
race, Borrmann macroscopic classifica-
tion, tumor location in the stomach,
length of gastrectomy, and immune re-
sponse to skin tests did not reach sta-
tistical significance, establishing that
the population in both groups were uni-
form (Table 1).
Criteria of Exclusion
1) Patients with preoperative meta-
static lesions (detected through physi-
cal examination, radiographic,
ultrasonographic, or laparoscopic
methods, or even by intraoperative
verification).
2) Patients with heart, hepatic, re-
nal or respiratory failure, infection,
anemia, or malnutrition that could not
be corrected before surgery.
Postoperative Clinical and Labora-
tory Evaluation
The sequence of clinical evaluation
and complementary exams carried out
for the patients in the two groups is
shown in Table 2.
Table 1 - Stratification of patients according to gender, race, Borrmann, neoplasia location, length of gastrectomy, and skin
sensitivity tests.
Group I Group II
(FAM) (Control) Statistical
Number % Number % Study*
Gender Male 15 60.00 21 75.00 x2=1.36
Female 10 40.00 7 25.00 p=0.2429 NS
Race Yellow 3 12.00 5 17.86 x2=0.35
White 17 68.00 18 64.28 p=0.8353
Black 5 20.00 5 17.86 NS
Borrmann I 1 4.16 3 10.71 x2=1.53
II 3 12.50 4 14.29 p=0.6732
III 18 75.00 17 60.71 NS
IV 2 8.33 4 14.29
Neoplastic 1/3 proximal 2 8.00 2 7.14 x2=1.20
Location in the 1/3 medial 4 16 8 28.57 p=0.8774
stomach 1/3 distal 14 56.00 13 46.43 NS
+ 1 region** 3 12.00 3 10.71
Stump 2 8.00 2 7.14
Length of Subtotal 15 60.00 17 60.71 x2=0.40
gastrectomy Total 5 20.00 7 25.00 p=0.8184
Enlarged tot.*** 5 20.00 4 14.29 NS
Skin Non-reactor 3 16.66 8 33.33 x2=1.48
Tests Reactive 15 83.33 16 66.66 p=0.2241 NS
* Statistical Test: two-tailed x2
** More than one region in the stomach
*** Total gastrectomy, splenectomy, and partial pancreatectomy.
NS: Without statistical difference
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Evaluation of nutritional status was
made according to the parameters sug-
gested by Seltzer et al.10: ideal body
weight percentage (IBW%), serum al-
bumin and number of lymphocytes, tri-
ceps skin fold measure (TSF%), and
arm muscular circumference (AMC%).
Chemotherapeutic method
The patients in Group I (FAM)
were admitted to the protocol after 2.36
± 0.64 months on average following
surgical treatment.
The dose and regime of the in-clinic
applications of chemotherapeutic drugs
were planned for 6 cycles that lasted 28
days each, as shown in Table 3.
The criteria for changing the che-
motherapeutic doses were based on the
hematological toxicity levels verified
by the number of white globules and/
or platelets on the day of drug appli-
cation (Table 4).
In case of progression of disease,
toxicity, or intolerance to medication,
the treatment was interrupted, and a
lack of response to the FAM protocol
was recorded.
The following methods were rou-
tinely used to detect disease progress:
clinical examination, thoracic X-ray,
gastroduodenal endoscopy, and ab-
dominal ultrasound.
RESULTS
Statistical analysis showed similar-
ity in the distribution of patients con-
cerning the nutritional status in both
study groups, with the exception of the
number of lymphocytes at the moment
of admission to the protocol, since
Group I (FAM) was made up by a
larger number of patients with moder-
ate or severe malnutrition than the
Group II (Control Group).
During the follow-up period
through the third chemotherapy cycle,
no statistical significance between the
study groups in relation to the 5 nutri-
Table 4 - Adequacy of chemotherapeutic doses in accordance with the number of
white globules and platelets.
FAM White globules Platelets
(Dose %) (Nº/mm3) (Nº/mm3)
100 > 4,000 > 100,000
50 2,500 - 4,000 75,000 - 100,000
0 < 2,500 < 75,000
Table 3 - Chemotherapy regime (FAM): doses, sequence,* and time of application
of drugs during treatment.
Doses  Cycles 1,3, and 5  Cycles 2,4 and 6
(mg/m2) Days 1 8 Days 1 8
5-Fluorouracil 600 X X X X
Adriamycin 30 X - X -
Mitomycin 10 X - - -
* the treatment was planned for six 28-day sequential cycles.
X = Chemotherapic application.
Table 2 - Sequence of clinical evaluation and the time of each post-operative
complementary exam.
Pre-chemo- Each 3rd 6th At the end
therapy Cycle cycle cycle of each year
Anamnesis X X X
Physical exam X X X
Weight check X X X
Height check X
Activity check (ECOG Scale) X X X
Nutritional Status check X X X
Complete hemogram and platelet count X X X
Hepatic function testing* X X X X
Renal function testing** X X X X
Radiological thorax exam X X X X
Per-oral endoscopic exam X X X X
Ultra-sound exam X X X
Electrocardiogram X X X
Late sensitivity skin testing*** X
*Hepatic function testing: alkaline phosphatase, aspartate amino transferase, alanine amino
transferase, gammaglutamyl-transpeptidase, total and fraction proteins and bilirubin.
**Renal function testing: Urea and creatinine.
***Late sensitivity skin testing: PPD, trichophytin, yeast, and Varidase.
ECOG: Eastern Cooperative Oncology Group.
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tional parameters considered was ob-
served. The same was observed in the
6th cycle, except in relation to IBW%,
because Group I (FAM) was made up
of a larger number of patients with nor-
mal check (two-tailed X² test p < 0.05).
In the first and second years of fol-
low-up, no statistically significant dif-
ference between the groups in relation
to the nutritional parameters was ob-
served. Likewise, no statistically sig-
nificant difference was observed be-
tween the groups in the third year, ex-
cept in relation to IBW% in Group I
(FAM), which was made up by a larger
number of eutrophic patients (two-
tailed X² test p < 0.05).
The synthesis of the nutritional
evaluation in the different periods of
study in accordance with the 5 param-
eters is shown on Table 5.
Effects of Chemotherapic Drugs
The gastrointestinal manifestations,
even if observed only once in each pa-
tient after operation for both groups,
are shown in Table 6.
Types and frequency of dermato-
logical complications are shown in
Table 7. All these complications re-
verted spontaneously (Table 7).
Neurological, cardiac, hepatic, or
renal toxicity was not presented by any
patient.
Hematological alterations were
more often seen in patients who re-
ceived chemotherapy, with leucopenia
being the most frequent manifestation
(Table 8). In one case myelodepression
motivated interruption of chemo-
therapy after the first cycle.
Due to either leucopenia or anemia,
patients in Group I (FAM) received on
average 74.4% of the total planned dos-
age of 5-fluorouracil, 78.9% of
Adriamycin, and 86.0% of mitomycin C.
Disease-free interval and tumoral re-
currence
In patients who underwent adjuvant
treatment by the FAM regimen, the av-
Table 8 -  Frequency of hematological alterations in the two study groups.
Group I Group II Statistical Study
(FAM) (C) (square x)
Leucopenia 75 0 - -
Anemia 7 4 x2=1.28 P=0.7421 NS
Table 6 -  Frequency of postoperative gastrointestinal manifestations in the two
study groups*.
Group I (FAM) Group II (C) Statistical Study
Nº = 25 Nº = 28 (square x)
Nausea 8 2 x2=3.83 p=0.0503 NS
Vomiting 6 5 x2=0.04 p=0.8327 NS
Diarrhea 4 5 x2=0.08 p=0.8519 NS
* Observed during the 6 cycles for the FAM Group and 6 periods for the Control Group.
Table 5 - Nutritional evaluation comparison between the FAM and control groups.
IBW% TSF% AMC% Lymphocytes Albumin
Admission NS NS NS NS S (FAM<C)
3rd C/P NS NS NS NS NS
6th C/P S (FAM>C) NS NS NS NS
1st year NS NS NS NS NS
2nd year NS NS NS NS NS
3rd year S (FAM>C) NS NS NS NS
Statistical analysis: X2 two-tailed test.
NS: No statistical difference.
S: Presence of statistical difference.
IBW%: Ideal body weight percentage TSF%: Triceps skin fold percentage.
AMC%: Arm muscular circumference percentage.
C/P: Cycle (FAM) or Period (Control).
Table 7 – Types and frequency of dermatological changes in the two study groups.
Group I (FAM) Group II (C)
Nº = 25 Nº = 28
Alopecia 7 0
Hyperchromic 2 0
stains on fingers
Purplish fingernails 2 0
erage disease-free interval was 27.15 ±
22.35 months.
In the control group, the average
disease-free interval was 23.07 ± 22.21
months (Student’s t test = 0.6700 and
p = 0.2520); therefore, there was no
statistically significant difference be-
tween the two groups of patients.
Gastrointestinal tumor recurrence
was not detected by endoscopic exami-
nation in any patient of both groups.
Tumoral recurrence site in the two
groups is shown on Table 9.
Survival
The average survival in patients in
group I (FAM) was 33.08 ± 19.43
months, and in group II (C) was 28.75
± 21.40 months (Student’s t test = 0.77
p = 0.2231 NS). The 5-year survival rate
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by the direct method (UICC TNM Gen-
eral Rules) for Group I (FAM) was
28.0% and for Group II (C) was 21.4%.
The survival curves were calculated
by Kaplan-Meyer’s method and are
shown in Graph 1.
In the initial phase (up to 21
months) a numerically higher survival
rate was observed in patients in Group
I (FAM).
The statistical study of the survival
rates, comparing both groups by the
Wilcoxon’s method did not show any
difference between the two curves ei-
ther considering just the first 21
months (W* = 1.21  p = 0.1131 NS)
or during the whole period of study
(W* = 1.14 p = 0.1271 NS).
DISCUSSION
The preliminary assessment of the
results of combined chemotherapy
(FAM regimen) suggested that better
survival rates could be obtained for pa-
tients operated on for advanced gastric
cancer without increased significant or
severe side effects11,12,13.
The objective of this study was to
verify the influence of the use of the
polychemotherapy (FAM) regime in
patients undergoing radical surgical
treatment of gastric cancer. The antine-
oplastic treatment was planned to be an
adjuvant; it was accepted that the op-
erative technique standardization in the
53 patients had reached its goal con-
cerning surgical radicality. The justifi-
cation for the use of the adjuvant
polychemotherapeutic regimen relies
on the survival rates after radical sur-
gical treatment in patients with stage
III tumors, which are between 19% and
33%14,15,16,17. It is also known that the
response rate to this chemotherapeutic
scheme varies from 7% to
42%12,18,19,10,21. Therefore, over 50% of
the patients surely did not respond to
the treatment.
Because the statistical analysis in-
dicated that the two groups studied
were homogeneous in relation to the
main clinical and laboratory variables,
and all patients had gastric cancer in
the same stage, it is reasonable to ac-
cept the obtained results as effectively
indicative of the only distinctive vari-
able, i.e., the FAM regimen.
After surgery, gastrointestinal com-
plaints were frequent but easily con-
trolled clinically with symptomatic
medication. We observed that patients
in the control group showed the same
degree of gastrointestinal symptoms as
the group receiving the antineoplastic
drugs (Table 6). This observation may
be explained as a consequence of the
physiologic modifications of the diges-
tive transit after gastric resection.
Neurological, renal, hepatic, or car-
diologic toxicity signals or infection
were not observed during the follow-
up period. Nor was any physical activ-
ity difference between groups observed
as evaluated by the ECOG scale. The
behavior similarity was remarkable in
both groups in relation to the 5 nutri-
tional parameters: measurement of
weight, albuminemia, number of serum
lymphocytes, triceps skin fold, and arm
muscular circumference.
The differences between the
groups, certainly arising from the use
of the FAM regime, were the tempo-
rary reduction of the lymphocyte num-
ber in 72% of cases and the dermato-
logical manifestations in 40%. The der-
matological finding motivated us to
change the pattern of administration of
chemotherapeutic drugs. Since they
were more frequent when high doses
of 5-fluorouracil are used, the occur-
rences of hyperchromic staining and
purplish fingernails must be monitored.
Cartei et al.22 observed the presence
of moderate leucopenia and
plateletopenia in spite of using the
FAM regimen in higher doses. Appar-
ently the degree of leucopenia is not
significantly influenced by the doses
Table 9  -  Tumoral recurrence site during the 5-year postoperative follow-up.
Site of recurrence Group I (FAM) Group II (C)
Nº % Nº %
Carcinomatosis 11 61.11 17 77.27
Hepatic 5 27.77 4 18.18
Bone 1 5.55 1 4.54
Lung 1 5.55 0 0.00
Total 18 100.00 22 100.00
x2 test:      x2 = 2.02    p = 0.5689   NS
Graph 1 - Survival Curve Kaplan-Meier Method.
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given, but rather by the individual sen-
sitivity to chemotherapeutic drugs21. In
own study, 74.4% of the planned dose
of 5-fluorouracil, 78.9% of the planned
dose of Adriamycin, and 86.0% of the
planned dose of mitomycin C were
given. A similar observation was de-
scribed by MacDonald et al.12, in
which the average quantity of planned
dosage started at 89% (first cycle), but
was progressively reduced to only 71%
of the planned dose by the sixth cycle.
In this study, the patients started
polychemotherapy 2.3 months on av-
erage after surgical treatment; this time
is longer than that established by the
review by Schlag’s23 and Torelli et al.24
of some studies carried out in Japan.
However, several Western study groups
started chemotherapy only in the post-
operative period and with an interval
similar to that used in the present in-
vestigation24, 25. The early introduction
of treatment could, theoretically, favor-
ably affect the survival results; how-
ever, the Hallisey et al.26 studies failed
to prove that hypothesis.
Regarding survival rates, there was
no statistical difference between groups
at the 5-year follow-up; only a higher
numerical, but not statistical signifi-
cant, survival was observed up to 21
months after surgery among the pa-
tients receiving chemotherapy. This re-
sult allows the supposition of some ac-
tivity of the drugs on the remaining
neoplastic cells that is not intense
enough to confirm the hypothesis for-
mulated by Macdonald et al.12 that the
objective response to the therapy would
correspond to an increase in the sur-
vival rate. This finding reinforces the
concept of Hallisey et al.27 that was en-
dorsed by Hermans et al.28 based on a
11-study analysis—that postoperative
adjuvant chemotherapy should not be
routinely used .
In the extensive experience of the
University of Georgetown group with
the FAM protocol29, an increase in sur-
vival was not observed, although a high
response percentage was detected.
Therefore, it is plausible to emphasize
the proposal made by Clark & Slevin30,
Kelsen31, Macdonald & Gohmann6,
Treat et al.29, Murad et al.32 and Dou-
glas33, who advocate that research for
new drugs and new therapeutic trials
are required to improve results of radi-
cal treatment of gastric cancer.
CONCLUSIONS
Nutritional status and incidence of
gastrointestinal manifestations after
surgical treatment of gastric cancer
were similar in the control group and
in patients treated by polychemo-
therapy (FAM).
There was neither occurrence of
cardiac, renal, neurological, or hepatic
toxicity nor of death arising from the
chemotherapeutic method per se.
Dermatological alterations and he-
matological toxicity occurred exclu-
sively in patients who received the
polychemotherapy, and these had mini-
mal clinical expression.
At the 5-year follow-up, there was
no difference between the rate and site
of the tumoral recurrence, the disease-
free interval, and the survival rate be-
tween study groups.
Therefore, chemotherapy under the
FAM regimen does not increase sur-
vival rate; it is not recommended for
routine use, but rather only for estab-
lished study protocols.
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Várias são as drogas e associações
propostas tanto para a quimioterapia
adjuvante como complementar visan-
do melhorar os resultados do tratamen-
to do câncer gástrico. Com o objetivo
de se analisar o impacto sobre o esta-
do nutricional e o índice de sobrevi-
vência no tratamento de 53 doentes
com câncer gástrico do estádio III da
classificação TNM, comparou-se  um
grupo controle composto de 28 doen-
tes submetidos apenas a ressecção  ra-
dical com outro grupo tratado com a
mesma conduta operatória seguida de
poliquimioterapia adjuvante pelo regi-
me FAM (5-fluorouracil, adriamicina e
mitomicina C) e composto de 25 do-
entes. Nestes últimos averiguou-se
também a toxicidade das drogas
antineoplásicas quanto à função hepá-
tica, renal, cardiológica, neurológica,
hematológica, gastrointestinal e
dermatológica. Por meio de análise es-
tatística afastou-se desigualdade entre
os dois grupos de estudo quanto ao
sexo, raça, tipo tumoral macroscópico
da classificação de Borrmann, localiza-
ção da neoplasia no estômago, exten-
são da ressecção gástrica e resposta às
provas cutâneas de sensibilidade retar-
dada na admissão. O tratamento
quimioterápico foi iniciado em média
2,3 meses após o tratamento cirúrgico.
Os doentes foram acompanhados clíni-
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ca e laboratorialmente pelo período de
5 anos tendo se chegado às seguintes
conclusões: 1) Foram semelhantes em
ambos os grupos de estudo a evolução
nutricional e a incidência de manifes-
tações gastrintestinais; 2) não ocorreu
toxicidade cardíaca, renal, neurológica
ou hepática e tampouco óbito em de-
corrência do método quimioterápico
em si; 3) alterações dermatológicas e
mielotoxicidade ocorreram exclusiva-
mente nos doentes que se submeteram
à poliquimioterapia; 4) não houve di-
ferença significante entre o índice e a
sede da recidiva tumoral, o tempo li-
vre de doença e os índices de sobrevi-
vência dos dois grupos de estudo após
cinco anos de seguimento portanto, a
quimioterapia pelo esquema FAM não
incrementa o referido índice.
DESCRITORES: Câncer gástrico.
Quimioterapia. Gastrectomia. Sobrevi-
vência. Esquema FAM.
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